Research progress in immunotherapy of advanced non-small cell lung cancer

Non-small cell lung cancer (NSCLC) poses a serious threat to people’s health. Its morbidity and mortality are among the highest among all malignant tumors, and there is an urgent need for more effective new treatment methods. In recent years, NSCLC immunotherapy has made great progress, the first PD-1 inhibitor nivolumab (Nivolumab, O drug) was approved by the US Food and Drug Administration (FDA) in March 2015, applying to the patients who progressed or has received platinum chemotherapy drugs in the past. Immunotherapy of advanced NSCLC has entered a new era. This article reviews the current research progress of NSCLC immunotherapy.